{rfName}
Ti

Indexed in

License and Use

Icono OpenAccess

Citations

3

Altmetrics

Analysis of institutional authors

Auñón CAuthorOsca-Gelis GAuthorMarcos-Gragera RAuthor

Share

April 25, 2023
Publications
>
Article
Sí

Time trends and survival of marginal zone lymphoma over 25 years in Girona, Spain (1994-2018)

Publicated to: Cancer Medicine. 12 (11): 12343-12353 - 2023-06-01 12(11), DOI: 10.1002/cam4.5935

Authors: Auñón, C; Sanvisens, A; Turon, E; Vidal-Vila, A; Puigdemont, M; Osca-Gelis, G; Eraso, A; Marcos-Gragera, R

Affiliations

CIBER Epidemiol & Publ Hlth CIBERESP, Girona, Spain - Author
Hosp Univ Dr Josep Trueta, Inst Catala Oncol, Inst Invest Biomed Girona Dr Josep Trueta IDIBGI, Registre Tumors Hosp RTH ICO ICS, Girona, Spain - Author
Inst Invest Biomed Girona Dr Josep Trueta IDIBGI, Epidemiol Unit, Girona, Spain - Author
Inst Invest Biomed Girona Dr Josep Trueta IDIBGI, Girona Cancer Registry, Inst Catala Oncol, Oncol, Girona, Spain - Author
Inst Invest Biomed Girona Dr Josep Trueta IDIBGI, Inst Catala Oncol, Radiat Oncol Dept, Girona, Spain - Author
Inst Recerca Contra Leucemia Josep Carreras, Girona, Spain - Author
Univ Girona, Dept Econ, Res Grp Stat Econometr & Hlth GRECS, Girona, Spain - Author
Univ Girona, Dept Med Sci, Girona, Spain - Author
Univ Girona, Dept Nursing, Girona, Spain - Author
See more

Abstract

Objective To analyze the incidence, incidence trends, and survival of marginal zone lymphomas (MZLs) in Girona and to describe these indicators based on the location in the case of extranodal MZLs.Methods Population-based study of MZL collected in the Girona Cancer Registry, 1994-2018. Sociodemographic data, tumor location, and stage were obtained from clinical records. Crude (CR) and age-adjusted (ASR(E)) incidence rates expressed per 100,000 person-years (p-y) were calculated. Joinpoint regression models were used for the trend analysis according to the MZL group. Five-year observed and net survival were analyzed.Results A total of 472 MZLs were included, 44 (9.3%) were nodal, 288 (61.0%) extranodal, 122 (25.9%) splenic, and the rest (n = 18) MZL, NOS. The CR for the MZL was 2.89 x 100,000 p-y (95% CI: 2.63-3.15), the ASR(E) was 3.26 x 100,000 p-y (95% CI: 2.97-3.57), and the annual percentage change (APC) was 1.6 (95% CI: 0.5-2.7). The ASR(E) for nodal MZL was 0.30 x 100,000 p-y (95% CI: 0.22-0.41) and showed an APC of 2.9% (95% CI: -16.4-26.6). For extranodal MZL, the ASR(E) was 1.98 x 100,000 p-y (95% CI: 1.76-2.23) and the APC was -0.4 (95% CI: -2.0-1.2). The most frequent locations of this type of MZL were the gastric (35.4%), skin (13.2%), and respiratory system (11.8%). The ASR(E) of the splenic MZL was 0.85 (95% CI: 0.71-1.02) with an APC of 12.8 (95% CI: 2.5-24.0). The 5-year net survival of MZL was 82.1% (95% CI: 76.3-86.5).Conclusions This study reveals differences in the incidence and trend of the incidence of MZL according to the subgroup, showing a significant increase in the overall MZL mainly due to splenic MZL type.

Keywords

autoimmune-diseasesb-cell lymphomaepidemiologyhematological malignancyhematologymarginal zone lymphomaneoplasmsnon-hodgkins-lymphomaspopulation-basedsub-typesubtypeunited-statesAdultAgedArticleCancerCancer epidemiologyCancer incidenceCancer registryCancer stagingCancer survivalCutaneous malt lymphomaEpidemiologyFemaleGastric malt lymphomaHematologyHumanHumansLymphoma, b-cell, marginal zoneMajor clinical studyMaleMarginal zone lymphomaMedical recordNodal marginal zone lymphomaPathologyPopulation researchPopulation-basedPopulation-based incidenceRegression modelRespiratory tract cancerRespiratory tract malt lymphomaRetrospective studySkin lymphomaSociodemographicsSpainSplenic marginal zone lymphomaStomachTrend studyTumor localization

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Cancer Medicine due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2023, it was in position , thus managing to position itself as a Q1 (Primer Cuartil), in the category Radiology, Nuclear Medicine and Imaging.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2025-12-13:

  • Europe PMC: 2

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-12-13:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 2.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 2 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 9.
  • The number of mentions on the social network X (formerly Twitter): 12 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Auñon Sanz, Carmen) and Last Author (Marcos Gragera, Rafael).

Awards linked to the item

Agencia de Gestio d'Ajuts Universitaris i de Recerca, Grant/Award Number: 2021 SGR 01511; Josep Carreras Leukaemia Research Institute, Grant/Award Number: FIJC1100